Social Media: 
Website
Colour:
- 
-
Website
Colour:
- -
Website
Colour:
- -
Updated July 2010
People in a variety of drug-related settings will need to know the legal status of various substances. This has implications for the legal possession, storage and supply of such substances. However, the majority of sites and literature only make reference to the most frequently encountered controlled drugs. This leaves workers uncertain as to whether drugs they encounter are not actually controlled drugs, or simply haven't been listed.
Drugs are "controlled" primarily by two linked pieces of legislation: the Misuse of Drugs Act which groups drugs by Class, and the Misuse of Drugs Regulations, which lists them by Schedule. The Classes of drugs, Class A, B, C defines the penalties for each group of drugs. The Schedules within the Misuse of Drugs Regulations describe the rules for possession, production and supply of each drug.
The following lists are comprehensive lists of drugs controlled under the Misuse of Drugs Act and described under the Medicines Act.
The original Misuse of Drugs Act 1971 can be viewed here.
There have been numerous changes to the legislation since; some have changed the powers within the act, or linked to the act. But the most frequent changes have been the addition of drugs to the list of Controlled Drugs or changes to their Class.
This situation hasn't been helped because there isn't a single "official" published accessible list of drugs Controlled under the Misuse of Drugs Act 1971.
The most up-to-date version is online here but, shockingly, has not been updated to reflect amendments since 2003, meaning a string of changes are not incorporated in to it.
Many of these changes are introduced by Statutory Instruments, but again, with no single list of SIs which have been applied to the Act, it is hard to be sure what changes have been introduced.
Different SIs need to be used to change the Misuse of Drugs Act and the Misuse of Drugs Regulations. The database of Statutory Instruments is here, and you can use the year/number (e.g. 2010/1143) to look up each SI.
The final element which makes the situation still more confusing is that whereas drugs were once generally added by name, they increasingly need to be added in broad groups, to cover potentially new drugs which are molecularly tweaked to bypass the legislation. Legislation is increasingly written in very broad terms to catch these molecular variants. While this ensures more drugs are covered by each clause it does make some of the legislation unintelligible. It also leaves confusion as to if some drugs are covered by the legislation or not.
In order to try and rectify this situation, KFx has posted an updated list of drugs controlled by Class and Schedule. This is built on the framework of the 1971 Act (as ammended) on the UK Statute Law Database and then incorporates SIs which have changed the Class of drugs.
In order to see which legislation introduced which changes, all changes are colour coded. Drugs which have been added or moved are shown in a colour, and at the end of the Drug Classes, a colour coded list of Statutory Instruments shows which legislation introduced this change.
The page lists drugs by class and by schedule seperately. The lists are alphabetical.
Drug Facts:
Misuse of Drugs Act, Schedule 2: Controlled Drugs
PART 1
1. The following substances and products, namely:
(a)
Acetorphine Benzethidine Carfentanil Desomorphine Ecgonine,
and any derivative ofecgonine which is convertible to ecgonine
or to cocaine Fentanyl Hydrocodone Isomethadone Ketobemidone Levomethorphan |
Mescaline Nicomorphine (3,6-dinicotinoylmorphine) Opium, whether raw, prepared or medicinal Pethidine Racemethorphan Sufentanil Tenocyclidine 4-Bromo-2,5-dimethoxy-x-methyl-phenethylamine |
(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(ba) the following phenethylamine derivatives, namely:
Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo-ß,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
ß-Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol
a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
a-Methyl-4-(methylthio)phenethylamine
ß,3,4,5-Tetramethoxyphenethylamine
ß,2,5-Trimethoxy-4-methylphenethylamine
(c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents.]
(d) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,
(e) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
2. Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
3. Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [F51 not being a substance for the time being specified in Part II of this Schedule].
4. Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
5. Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.
6. Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.
PART II
1. The following substances and products, namely:
(a)
Acetylhydrocodeine Cannabis and cannabis resin Dihydrocodeine Ethylmorphine (3-EEthylmorphine) Glutethimide Lefetamine |
Mecloqualone Nicocodine Pentazocine Zipeprol |
(aa) Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say,
(ab) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say, .
(b) any 5,5 disubstituted barbituric acid.
(c) [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.
Nabilone.
Any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.
2. Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.
2a. Any ester or ether of cannabinol or of a cannabinol derivative or of a substance for the time being specified in paragraph 1(c) of this Part of this Schedule
3. Any salt of a substance for the time being specified in paragraph 1 or 2 or 2A of this Part of this Schedule.
4. Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.
PART III
1: The following substances and products, namely:
(a)
|
Alprazolam Benzphetamine Camazepam Delorazepam Estazolam Fencamfamin Gamma-butyrolactone Halazepam Ketamine |
Loprazolam Mazindol Methyprylone Nimetazepam Oxazepam Pemoline Temazepam N-Ethylamphetamine Zolpidem |
(b)
Atamestane Bolandiol Calusterone Danazol Enestebol Fluoxymesterone Gestrinone 3–Hydroxy–5a–androstan–17–one Mebolazine |
Nandrolone Oripavine Prasterone Quinbolone Roxibolone Silandrone Testosterone |
(c) any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say,
(ca) 1–benzylpiperazine or any compound structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways:
(d) any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above;
(e) Chorionic Gonadotrophin (HCG).
Clenbuterol.
Non-human chorionic gonadotrophin.
Somatotropin.
Somatrem.
Somatropin
Zeranol
Zilpaterol
2. Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule [not being phenylpropanolamine.]
3. Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
4. Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule.
Meaning of certain Expressions used in this Schedule
For the purposes of this Schedule the following expressions (which are not among those defined in section 37(1) of this Act) have the meanings hereby assigned to them respectively, that is to say:
The colours below are linked to the drug entries in the tables and lists above to make it easy to see which drugs were added by which SI in the tables above.
SI2001/3932
This Order adds thirty-six substances to Schedule 2 to the Misuse of Drugs
Act 1971 which specifies drugs which are subject to control under the Act.
The thirty-six substances are phenethylamine derivatives which are not covered
by the definition in paragraph 1(c) of Part I of Schedule 2 to the 1971 Act.
Thirty-five of the substances are added as Class A drugs; and a-Methylphenethylhydroxylamine
is added as a Class B drug.
SI2003/1243
This Order adds eight substances to Schedule 2 to the Misuse of Drugs Act 1971
which specifies drugs which are subject to control under the Act. Two of
the substances, Dihydroetorphine and Remifentanil, are added as Class A drugs;
and the remaining six, 4-Androstene-3, 17-dione; 5-Androstene-3, 17-diol;
4-Hydroxy-n-butyric acid; 19-Nor-4-Androstene-3; 17-dione, 19-Nor-5-Androstene-13,
17-diol and Zolpidem, are added as Class C drugs.
SI2005/3178
This Order inserts Ketamine into Part 3 of Schedule 2 to the Misuse of Drugs
Act 1971, which specifies drugs which are subject to control under that Act
as Class C drugs.
SI2006/3331
This Order reclassifies methylamphetamine, previously a Class B drug, as a
Class A drug by moving it from Part 2 of Schedule 2 to the Misuse of Drugs
Act 1971 to Part 1 of that Schedule.
SI2008/3130
This Order reclassifies cannabis, cannabis resin, cannabinol and cannabinol
derivatives from Class C to Class B drugs for the purposes of control under
the Misuse of Drugs Act 1971. In addition, any substance which is an ester
or ether of cannabinol or of a cannabinol derivative is reclassified as a
Class B drug.
SI2009/3209
This Order adds synthetic cannabinoid receptor agonists to Part 2 of Schedule
2 to the Misuse of Drugs Act 1971 (“the Act”) which specifies drugs
which are subject to control as Class B drugs under the Act. In addition,
the Order adds Gamma-butyrolactone (GBL), 1,4–butanediol (1,4–BD),
15 anabolic steroids, two non-steroidal agents, Oripavine, 1–benzylpiperazine
(BZP) and a group of substituted piperazines to Part 3 of Schedule 2 to the
Act which specifies drugs which are subject to control as Class C drugs under
the Act.
SI2010/1207
This Order adds 4-methylmethcathinone (commonly known as mephedrone) and other
cathinone derivatives to Part 2 of Schedule 2 to the Misuse of Drugs Act
1971 (“the Act”) which specifies drugs which are subject to control
as Class B drugs under the Act. It does not include cathinones and cathinone
derivatives already controlled under the Act or bupropion.
SI2010/1833
This Order adds a further group of cathinone derivatives (including naphthylpyrovalerone,
commonly known as naphyrone) to Part 2 of Schedule 2 to the Misuse of Drugs
Act 1971 which specifies drugs which are subject to control as Class B drugs
under that Act.
Misuse Of Drugs Regulations 2001
The Misuse of Drugs Regulations (1985) with various amendments were reviewed and rationalised. The end result was a revised set of regulations that came into force on February 1st 2002. The revised regulations, as introduced by SI2001/3998 form the basis of the tables below and can be viewed here.
Since 2001, the Misuse of Drugs Regulations 2001 have been further amended by SI; some of these concerned the regulations themselves while others added new drugs to the Schedules. Where drugs have been added to the schedules since 2005, these are indicated on the tables below in colour. The relevant Statutory Instrument which introduced the change is listed at the bottom in the same colour with its explanatory note.
The Misuse of Drugs Regulations creates 5 Schedules, governing possession and supply of the drugs controlled under the Misuse of Drugs Act. The regulations also govern prescribing, safe custody, importation, exportation, production and record keeping.
When considering who can possess or supply Controlled Drugs (CDs), it is more important to look at the Schedule of the drug, rather than the Class. The Class determines how dangerous a drug is perceived to be, and penalties relating to the drug. The Schedule defines who may be in possession of or supply each drug, and under what conditions.
For an understanding of the requirements related to each schedule as applicable in lay-settings please consult the LEGISLATION document in the Resources section.
CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27
1. The following substances and products, namely -
(a) Bufotenine
1,4-Butanediol
Cannabinol
Cannabinol derivatives not being dronabinol or its stereoisomers
Cannabis and cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1,
2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol
Eticyclidine
Etryptamine
Fungus (of any kind) which contains psilocin or an ester of psilocin
Gamma-butyrolactone
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl]
oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl]
acetate
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a,
7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol
Lysergamide
Lysergide and other N-alkyl derivatives of lysergamide
Mescaline
Methcathinone
4–methylmethcathinone
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy-a-methylphenethylamine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
2,5-Dimethoxy-,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex
(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(c) the following phenethylamine derivatives, namely -
Allyl(-methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(-methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo-ß,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(-methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(-methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(-methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
ß-Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(-Methyl-3,4-methylenedioxyphenethylamino)ethanol
-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
-Methyl-4-(methylthio)phenethylamine
ß,3,4,5-Tetramethoxyphenethylamine
ß,2,5-Trimethoxy-4-methylphenethylamine
(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, -methylphenethylamine, an N-alkyl--methylphenethylamine, -ethylphenethylamine, or an N-alkyl--ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;
(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say:
(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say -
(g) 1–benzylpiperazine or any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways— .
(h) [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone; .
(i) 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol; .
(j) [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate; .
(k) 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol; .
(l) any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; .
(m) any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; .
(n) any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; .
(o) any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; .
(p) any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.
(q) Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say, .
(r) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say, .
2. Any stereoisomeric form of a substance specified in paragraph 1.
3. Any ester or ether of a substance specified in paragraph 1 or 2.
4. Any salt of a substance specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 21, 23, 26 AND 27
1. The following substances and products, namely-
|
Acetorphine Benzethidine Carfentanil Desomorphine Ecgonine, and any derivative of Fentanyl Hydrocodone Isomethadone Ketobemidone |
Levomethorphan Medicinal opium Nabilone Oxycodone Pethidine Racemethorphan Sufentanil Thebacon Zipeprol 4-Cyano-2-dimethylamino-4,4-diphenylbutane |
2. Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.
3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.
4. Any salt of a substance specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
6. The following substances and products, namely -
|
Acetyldihydrocodeine Codeine Dextropropoxyphene Ethylmorphine (3-ethylmorphine) Fenethylline Glutethimide Lefetamine |
Mecloqualone Nicocodine Phenmetrazine Quinalbarbitone |
7. Any stereoisomeric form of a substance specified in paragraph 6.
8. Any salt of a substance specified in paragraph 6 or 7.
9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.
CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 (EXCEPT TEMAZEPAM), 16, 18, 22, 23, 24, 26 AND 27
The following substances, namely-
Benzphetamine Cathine Diethylpropion Ethchlorvynol Flunitrazepam
|
Mazindol Methylphenobarbitone Pentazocine Temazepam |
(b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.
2 Any stereoisomeric form of a substance specified in paragraph 1 not being
phenylpropanolamine.
3 Any salt of a substance specified in paragraph 1 or 2.
4 Any preparation or other product containing a substance specified in any
of paragraphs 1 to 3, not being a preparation specified in Schedule 5.
CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REG ULATIONS 22, 23, 26 AND 27
1. The following substances and products, namely-
|
Alprazolam Bromazepam Camazepam Diazepam Estazolam Fencamfamin GammahydroxyButyrate (GHB) Halazepam |
Ketamine Loprazolam Medazepam Nimetazepam Oxazepam Pemoline Tetrazepam N-Ethylamphetamine Zolpidem |
2. Any stereoisomeric form of a substance specified in paragraph 1.
3. Any salt of a substance specified in paragraph 1 or 2.
4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.
CONTROLLED DRUGS EXCEPTED FROM
THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT;
EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM THE PROHIBITION
ON IMPORTATION
AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM
OF A MEDICINAL PRODUCT
BY ANY PERSON FOR ADMINISTRATION TO HIMSELF; AND SUBJECT TO THE REQUIREMENTS
OF REGULATIONS 22, 23, 26 AND 27
1. The following substances, namely-
|
5a–Androstane–3,17–diol |
Methenolone |
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -
3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.
4. The following substances, namely:
Chorionic Gonadotrophin (HCG)
Clenbuterol
Non-human chorionic gonadotrophin
Somatotropin
Somatrem
Somatropin
Zeranol
Zilpaterol
5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.
6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.
7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.
CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON |IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26
1 - (1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.
(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.
2. Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.
3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.
4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.
5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity ofatropine sulphate equivalent to at least 5% of the dose of difenoxin.
6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.
7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.
8. Any powder of ipecacuanha and opium comprising-
10% opium, in powder,
10% ipecacuanha root, in powder, well mixed with
80% of any other powdered ingredient containing no controlled drug.
9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.
The colours below are linked to the drug entries in the tables and lists above to make it easy to see which drugs were added by which SI in the tables above.
SI 2003/3998
These Regulations amend the Misuse of Drugs Regulations 2001 by adding two
substances to paragraph 1 of Schedule 2 (controlled drugs subject to the
requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27) two
substances to Part I of Schedule 4 (controlled drugs subject to the requirements
of regulations 22, 23, 26 and 27) and four substances to Part II of Schedule
4 (controlled drugs excepted from the prohibition on possession when in the
form of a medicinal product; excluded from the application of offences arising
from the prohibition on importation and exportation when imported or exported
in the form of a medicinal product by any person for administration to himself;
and subject to the requirements of regulations 22, 23, 26 and 27).
2005/1653
Regulation 2(3) inserts "a fungus containing psilocin or an ester of psilocin" into
Schedule 1 to the 2001 Regulations, enabling the Secretary of State to issue
a licence under regulation 5 of the 2001 Regulations in respect of the production,
supply, offer to supply or possession of those fungi.
SI 2005/3372
These Regulations insert Ketamine into Part 1 of Schedule 4 to the Misuse of
Drugs Regulations 2001.
SI2009/3135
This Order amends the Misuse of Drugs (Designation) Order 2001 by inserting
into Part 1 of the Schedule to that Order gamma–butyrolactone (GBL),
1,4–butanediol (1,4–BD), 1–benzylpiperazine (BZP) and a group
of substituted piperazines and synthetic cannabinoid receptor agonists excluding
nabilone. Regulation 3 specifically excludes two substituted piperazines
from the designation.
SI 2009/3136
These Regulations insert 1–benzylpiperazine (BZP), all but two of a group
of substituted piperazines and the synthetic cannabinoid agonists into Schedule
1 to the Misuse of Drugs Regulations 2001 (“the 2001 Regulations”),
save for nabilone which is inserted into Schedule 2 to the 2001 Regulations
along with oripavine. The two other substituted piperazines are inserted into
Part 1 of Schedule 4 to the 2001 Regulations and 15 anabolic steroids and 2
non-steroidal agents are inserted into Part 2 of that Schedule. The schedule
in which a controlled drug is placed primarily affects the extent to which
the drug can be lawfully imported, exported, produced, supplied or possessed
and dictates the record keeping, labelling and destruction requirements in
relation to those drugs.
Gamma–butyrolactone (GBL) and 1,4–butanediol (1,4–BD) are not inserted into any schedule. However, regulation 3 makes it lawful to import, export, produce, supply, offer to supply or possess these substances except where a person does so, knowing or believing that it will be used for the purpose of human ingestion other than as a flavouring in food.
SI 201011/43
This Order amends the Misuse of Drugs (Designation) Order 2001 by inserting
into Part 1 of the Schedule to that Order 4-methylmethcathinone (commonly
referred to as mephedrone) and other cathinone derivatives.
SI 2010/1144
These Regulations insert 4–methylmethcathinone (commonly referred to as
mephedrone) and other cathinone derivatives into Schedule 1 to the Misuse of
Drugs Regulations 2001 (“the 2001 Regulations”). The schedule in
which a controlled drug is placed primarily affects the extent to which the
drug can be lawfully imported, exported, produced, supplied or possessed and
dictates the record keeping, labelling and destruction requirements in relation
to that drug.
SI2010/1800
This Order amends the Misuse of Drugs (Designation) Order 2001 by inserting
into Part 1 of the Schedule to that Order a further group of cathinone derivatives
(including naphthylpyrovalerone, commonly known as naphyrone).
Copyright © 2024 KFx